ArticleTranslational cancer research2026
Rosa roxburghii Tratt fruit polysaccharides inhibit proliferation and induce apoptosis in human cervical cancer cell line.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a major malignancy seriously threatening women's health. Rosa roxburghii Tratt fruit polysaccharides (RTFP), a natural extract possessing diverse biological activities, can inhibit tumors through mechanisms such as inducing apoptosis and cell cycle arrest. However, the potential effects of RTFP on cervical cancer and the associated molecular mechanisms remain incompletely elucidated. Therefore, this study aimed to investigate the effects of RTFP sourced on the proliferation, migration, invasion, and apoptosis of human cervical cancer cell line. Methods: Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. HeLa cells were treated with RTFP at concentrations of 2, 4, 6, 8, and 10 mg/mL for 24, 48, and 72 h. Cell migration and invasion were evaluated using scratch wound healing and Transwell assays, respectively, after exposure to RTFP (3 and 6 mg/mL) for 24 and 48 h. For cell cycle and apoptosis analysis, cells treated with RTFP (3 and 6 mg/mL) for 48 h were analyzed by flow cytometry. The messenger RNA (mRNA) and protein expression levels of cell cycle regulators (CDK-1 and cyclin B1) and apoptosis-related markers (Bax, Bcl-2, caspase-3, caspase-8, and caspase-9) were quantified by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot, respectively, following 48 h of treatment with RTFP (3 and 6 mg/mL). All experiments were performed in three independent replicates (n=3), and data are presented as mean ± standard deviation (SD). Results: RTFP inhibited the proliferation, migration, and invasion of HeLa cells in a time- and dose-dependent manner (P<0.01). It induced cell cycle arrest at the G2/M phase (P<0.01) and downregulated the protein expression of CDK-1 and cyclin B1 (P<0.05). Additionally, RTFP promoted apoptosis through modulating apoptosis-related proteins: it upregulated the pro-apoptotic proteins Bax, caspase-3, caspase-8, and caspase-9 (P<0.05), while downregulated the anti-apoptotic protein Bcl-2 (P<0.01). Conclusions: RTFP inhibits the proliferation, migration, and invasion of HeLa cells, arrests the cell cycle at the G2/M phase, and induces apoptosis. These
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.